HomeCompareTCDA vs XYLD

TCDA vs XYLD: Dividend Comparison 2026

TCDA yields 1851.85% · XYLD yields 11.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCDA wins by $4863045258.29M in total portfolio value
10 years
TCDA
TCDA
● Live price
1851.85%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4863045258.31M
Annual income
$4,396,067,798,536,862.00
Full TCDA calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
11.20%
Share price
$38.36
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$3,351.03
Full XYLD calculator →

Portfolio growth — TCDA vs XYLD

📍 TCDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCDAXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCDA + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCDA pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCDA
Annual income on $10K today (after 15% tax)
$157,407.41/yr
After 10yr DRIP, annual income (after tax)
$3,736,657,628,756,332.50/yr
XYLD
Annual income on $10K today (after 15% tax)
$952.37/yr
After 10yr DRIP, annual income (after tax)
$2,848.38/yr
At 15% tax rate, TCDA beats the other by $3,736,657,628,753,484.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCDA + XYLD for your $10,000?

TCDA: 50%XYLD: 50%
100% XYLD50/50100% TCDA
Portfolio after 10yr
$2431522629.17M
Annual income
$2,198,033,899,270,106.50/yr
Blended yield
90.40%
📊

Analyst Conviction Gap

Where Wall Street is split right now

TCDA
Analyst Ratings
1
Buy
2
Hold
1
Sell
Consensus: Hold
Price Target
$16.00
+14714.8% upside vs current
Range: $16.00 — $16.00
Altman Z
-16.7
Piotroski
1/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCDA buys
0
XYLD buys
0
No recent congressional trades found for TCDA or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCDAXYLD
Forward yield1851.85%11.20%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4863045258.31M$25.9K
Annual income after 10y$4,396,067,798,536,862.00$3,351.03
Total dividends collected$4829695825.56M$20.2K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TCDA vs XYLD ($10,000, DRIP)

YearTCDA PortfolioTCDA Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$195,885$185,185.19$10,840$1,120.44+$185.0KTCDA
2$3,599,787$3,390,190.12$11,786$1,249.59+$3.59MTCDA
3$62,077,580$58,225,807.67$12,854$1,397.78+$62.06MTCDA
4$1,004,826,655$938,403,644.40$14,063$1,568.33+$1004.81MTCDA
5$15,271,043,115$14,195,878,594.10$15,434$1,765.19+$15271.03MTCDA
6$217,970,436,268$201,630,420,135.20$16,995$1,993.14+$217970.42MTCDA
7$2,922,911,796,978$2,689,683,430,171.31$18,777$2,257.95+$2922911.78MTCDA
8$36,835,711,310,169$33,708,195,687,401.73$20,818$2,566.58+$36835711.29MTCDA
9$436,427,532,502,759$397,013,321,400,878.75$23,163$2,927.50+$436427532.48MTCDA
10$4,863,045,258,314,815$4,396,067,798,536,862.00$25,865$3,351.03+$4863045258.29MTCDA

TCDA vs XYLD: Complete Analysis 2026

TCDAStock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Full TCDA Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this TCDA vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCDA vs SCHDTCDA vs JEPITCDA vs OTCDA vs KOTCDA vs MAINTCDA vs QYLDTCDA vs JEPQTCDA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.